The inclusion of Leqembi in this list marks a meaningful step toward expanding access to early Alzheimer’s Disease (AD) treatment in China, the company states.

The Commercial Insurance Innovative Drug List

The Commercial Insurance Innovative Drug List is based on new policies of the Chinese government to support the development and access of innovative medicines. The list aims to help narrow the coverage gap between the basic reimbursement system under the National Reimbursement Drug List (NRDL) and innovative medicines that address areas of significant unmet need. Based on the Commercial Insurance Innovative Drug List, commercial insurance companies will discuss and reach an agreement with pharmaceutical companies regarding coverage details and develop insurance products focusing on the listed medicines. The Commercial Insurance Innovative Drug List is scheduled to take effect on January 1, 2026.

Eisai launched Leqembi in China in June 2024 and has delivered the product in the private market.